| | Location: Home » Cancer Education » Prostate Cancer - Current Issues, New Approaches (European Urology, Vol 29, Suppl 2) | |
|
| Prostate Cancer - Current Issues, New Approaches (European Urology, Vol 29, Suppl 2) |  | Creator: Roger S. Kirby
Publisher: S Karger Pub
Category: Book
Buy New: $68.00
as of 2/8/2012 04:58 PST details
In Stock
New (1) Used (1) from $68.00
Seller: Amazon.com
Languages: English (Unknown), English (Original Language), English (Published)
Media: Paperback
Pages: 140
Shipping Weight (lbs): 0.2
Dimensions (in): 11.1 x 8 x 0.1
ISBN: 3805563140
EAN: 9783805563147
Shipping: Eligible for FREE Super Saver Shipping
Availability: Usually ships in 24 hours
| | |
| Editorial Reviews:
Product Description
In many countries prostate cancer is the most frequently diagnosed cancer in men and it is expected to become a major cause of cancer mortality. For patients with locally confined disease, a radical prostatectomy or radiotherapy leads to high survival rates (around 75%) [1]. However, it is not ceratin whether the risks of radical prostatectomy outweigh the benefits in localised disease. Moreover, at presentation, around 50% of patients have disease which is too advanced for potentially curative therapy, and these patients have a poor prognosis with an average life expectancy of around 2 years. Combined androgen blockade (CAB), the addition of an antiandrogen to a luteinising hormone releasing hormone (LHRH) analogue, is becoming the standard treatment for patients with advanced prostate cancer. This is an appealing option as androgens from both the testes and adrenal are blocked. There is, however, continuing debate as to whether CAB is more effective than castration alone. This is despite several, prospective, randomised trials and a large meta-analysis indicating advantages in terms of disease-free progression and survival CAB [205]. Screening programmes have been proposed to detect and possibly treat prostate cancer at an earlier stage, but their benefits are questionable in view of the natural history of the disease. Many other questions remain, for example: should healthcare resources be targeted to chemoprevention, and should patients with hormone-resistant disease only be managed with supportive care? It was with all of these issues in mind that the congress `Prostate cancer, current issues, new approaches' evolved, steered by an eminent scientific committee and supported by an educational grant from Zeneca Pharmaceuticals, held in the Queen Elizabeth II Conference Centre, London, England, 19-21 October 1995, the congress atracted over 800 delegates from all over the world. The scientific programme opened with a series of six debates covering contentious current issues in prostate cancer such as: will the incidence of the disease double by the year 2030? the arguments for the against were presented by experts in the field (who did not necessarily hold the view that they presented). After each debate an interactive voting system was used to seek the opinions of delegates, and the results of these votes are included in these proceedings. This was followed by state-of-the-art presentations by leading exponents in the area on four key topics: epidemiology, prevention and screening; the treatment of localised disease and of hormone-resistant disease, and CAB. Professor David Crawford (United States) presented the latest results of the intergroup study (0036) demonstrating advantages for CAB in overall survival and progression over an LHRH analogue alone, particularly in patients with metastatic disease.
|
| |
| In Stock
|
|
|
| |
|